Ototoxicity in Children With High-Risk Neuroblastoma: Prevalence Risk Factors and Concordance of Grading Scales—A Report From the Childrens Oncology Group

摘要

PurposePlatinum-based therapy is the mainstay for management of high-risk neuroblastoma. Prevalence of platinum-related ototoxicity has ranged from 13% to 95% in previous reports; variability is attributable to small samples and disparate grading scales. There is no consensus regarding optimal ototoxicity grading. Furthermore, prevalence and predictors of hearing loss in a large uniformly treated high-risk neuroblastoma population are unknown. We address these gaps in our study.